About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 76  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2009  |  Volume : 2  |  Issue : 2  |  Page : 73-78

Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results

1 Vitreo-retina Unit, Aravind Eye Hospital, Coimbatore, India; Department of Ophthalmology, Sultan Qaboos University Hospital, Muscat, Sultanate Of Oman
2 Vitreo-retina Unit, Aravind Eye Hospital, Coimbatore, India
3 Department of Ophthalmology, Sultan Qaboos University Hospital, Muscat, Sultanate Of Oman

Correspondence Address:
George J Manayath
Department of Ophthalmology, Sultan Qaboos University Hospital, Post Box: 38, Al Khod, Muscat, Sultanate Of Oman-123

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-620X.53036

Rights and Permissions

Background: There is no proven effective treatment for vision loss in central retinal vein occlusion (CRVO). Bevacizumab has been reported in small series with limited follow-up, to have a positive effect in reducing cystoid macular edema (CME) and improving vision in CRVO. Purpose: To report long-term results with the use of bevacizumab in CRVO. Materials and Methods: Prospective interventional case series included 15 patients, serially evaluated with best corrected visual acuity (BCVA), optical coherence tomography (OCT), fluorescein angiography, and tonometry. Results were statistically analyzed. Results: Mean follow-up was 12 3.6 months (range, 6−18 months); mean number of injections was 2.2 (range, 1−4) per patient. Statistically significant reduction of macular thickness (P < 0.001) was seen at six weeks (mean, 346 ); three months (mean, 353 ); six months (mean, 348 ); and final follow-up (mean, 342 ). Significant BCVA improvement was seen at six weeks (mean, 0.27 logMAR), three months (mean, 0.3 logMAR), three months (0.15 logMAR), and final follow-up (mean, 0.21 logMAR) (P = 0.009). Also, 73.3% patients had BCVA improvement at the last follow-up. Conclusion: Intravitreal bevacizumab is an effective treatment option for CME in CRVO patients. Reinjections at appropriate timing, based on the OCT findings, are important for better visual outcome.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded795    
    Comments [Add]    
    Cited by others 3    

Recommend this journal